This paper presents MRAS speed sensorless control of induction motor using type-2 fuzzy logic controller (T2FLC). These controllers replace the PI ones, in the new MRAS strategy proposed in Benlaloui et al. (IEEE Trans Energy Convers 30(2):588–595, 2015), in order to improve the induction motor performances and robustness at low speed region. Indeed, the choice of these controllers is made because of their adaptation-based schemes which permit to handle nonlinear uncertain systems without the need of precise mathematical model required when using PI controllers. Comparative study had shown a better rejection of disturbance and high insensitivity to stator resistance compared to the PI and the T1FLC controllers. The effectiveness of the proposed speed-based T2FLC estimation method and its good robustness are validated by simulation and by experimental results.

This paper presents MRAS speed sensorless control of induction motor using type-2 fuzzy logic controller (T2FLC). These controllers replace the PI ones, in the new MRAS strategy proposed in Benlaloui et al. (IEEE Trans Energy Convers 30(2):588–595, 2015), in order to improve the induction motor performances and robustness at low speed region. Indeed, the choice of these controllers is made because of their adaptation-based schemes which permit to handle nonlinear uncertain systems without the need of precise mathematical model required when using PI controllers. Comparative study had shown a better rejection of disturbance and high insensitivity to stator resistance compared to the PI and the T1FLC controllers. The effectiveness of the proposed speed-based T2FLC estimation method and its good robustness are validated by simulation and by experimental results.

This paper presents MRAS speed sensorless control of induction motor using type-2 fuzzy logic controller (T2FLC). These controllers replace the PI ones, in the new MRAS strategy proposed in Benlaloui et al. (IEEE Trans Energy Convers 30(2):588–595, 2015), in order to improve the induction motor performances and robustness at low speed region. Indeed, the choice of these controllers is made because of their adaptation-based schemes which permit to handle nonlinear uncertain systems without the need of precise mathematical model required when using PI controllers. Comparative study had shown a better rejection of disturbance and high insensitivity to stator resistance compared to the PI and the T1FLC controllers. The effectiveness of the proposed speed-based T2FLC estimation method and its good robustness are validated by simulation and by experimental results.

This paper presents MRAS speed sensorless control of induction motor using type-2 fuzzy logic controller (T2FLC). These controllers replace the PI ones, in the new MRAS strategy proposed in Benlaloui et al. (IEEE Trans Energy Convers 30(2):588–595, 2015), in order to improve the induction motor performances and robustness at low speed region. Indeed, the choice of these controllers is made because of their adaptation-based schemes which permit to handle nonlinear uncertain systems without the need of precise mathematical model required when using PI controllers. Comparative study had shown a better rejection of disturbance and high insensitivity to stator resistance compared to the PI and the T1FLC controllers. The effectiveness of the proposed speed-based T2FLC estimation method and its good robustness are validated by simulation and by experimental results.

New 2-pyridone derivatives were hemi-synthetised in situ using essential oils of endemic Algerian plants; Ammodaucus Leucotrichus and eucalyptus citriodora as source of chiral aldehydes (perillaldehyde and citronellal respectively). The one pot reaction was carried out in Ethanol including cyanoacetohydrazide, essential oil, and malononitrile. The reaction mixture was catalysed by potassium carbonate. In the present work, two new compounds of highly functionalized 2-pyridones were obtained as privileged medicinal scaffolds. The structures of 2-pyridone derivatives were confirmed by 1H NMR, 13C and 2D

New 2-pyridone derivatives were hemi-synthetised in situ using essential oils of endemic Algerian plants; Ammodaucus Leucotrichus and eucalyptus citriodora as source of chiral aldehydes (perillaldehyde and citronellal respectively). The one pot reaction was carried out in Ethanol including cyanoacetohydrazide, essential oil, and malononitrile. The reaction mixture was catalysed by potassium carbonate. In the present work, two new compounds of highly functionalized 2-pyridones were obtained as privileged medicinal scaffolds. The structures of 2-pyridone derivatives were confirmed by 1H NMR, 13C and 2D

New 2-pyridone derivatives were hemi-synthetised in situ using essential oils of endemic Algerian plants; Ammodaucus Leucotrichus and eucalyptus citriodora as source of chiral aldehydes (perillaldehyde and citronellal respectively). The one pot reaction was carried out in Ethanol including cyanoacetohydrazide, essential oil, and malononitrile. The reaction mixture was catalysed by potassium carbonate. In the present work, two new compounds of highly functionalized 2-pyridones were obtained as privileged medicinal scaffolds. The structures of 2-pyridone derivatives were confirmed by 1H NMR, 13C and 2D

New 2-pyridone derivatives were hemi-synthetised in situ using essential oils of endemic Algerian plants; Ammodaucus Leucotrichus and eucalyptus citriodora as source of chiral aldehydes (perillaldehyde and citronellal respectively). The one pot reaction was carried out in Ethanol including cyanoacetohydrazide, essential oil, and malononitrile. The reaction mixture was catalysed by potassium carbonate. In the present work, two new compounds of highly functionalized 2-pyridones were obtained as privileged medicinal scaffolds. The structures of 2-pyridone derivatives were confirmed by 1H NMR, 13C and 2D

New 2-pyridone derivatives were hemi-synthetised in situ using essential oils of endemic Algerian plants; Ammodaucus Leucotrichus and eucalyptus citriodora as source of chiral aldehydes (perillaldehyde and citronellal respectively). The one pot reaction was carried out in Ethanol including cyanoacetohydrazide, essential oil, and malononitrile. The reaction mixture was catalysed by potassium carbonate. In the present work, two new compounds of highly functionalized 2-pyridones were obtained as privileged medicinal scaffolds. The structures of 2-pyridone derivatives were confirmed by 1H NMR, 13C and 2D

New 2-pyridone derivatives were hemi-synthetised in situ using essential oils of endemic Algerian plants; Ammodaucus Leucotrichus and eucalyptus citriodora as source of chiral aldehydes (perillaldehyde and citronellal respectively). The one pot reaction was carried out in Ethanol including cyanoacetohydrazide, essential oil, and malononitrile. The reaction mixture was catalysed by potassium carbonate. In the present work, two new compounds of highly functionalized 2-pyridones were obtained as privileged medicinal scaffolds. The structures of 2-pyridone derivatives were confirmed by 1H NMR, 13C and 2D

New 2-pyridone derivatives were hemi-synthetised in situ using essential oils of endemic Algerian plants; Ammodaucus Leucotrichus and eucalyptus citriodora as source of chiral aldehydes (perillaldehyde and citronellal respectively). The one pot reaction was carried out in Ethanol including cyanoacetohydrazide, essential oil, and malononitrile. The reaction mixture was catalysed by potassium carbonate. In the present work, two new compounds of highly functionalized 2-pyridones were obtained as privileged medicinal scaffolds. The structures of 2-pyridone derivatives were confirmed by 1H NMR, 13C and 2D

Background

Diabetes mellitus is a serious complex multifactorial disorder that imposes huge health and economic burden on societies. Because the currently available medications have many drawbacks, it's important to look for alternative therapies. Medicinal plants utilized in folk medicine are ideal candidates. Therefore, this work assessed the antidiabetic action of n-butanol extract from the whole plant Atractylis flava Desf (BEAF). These ethnomedicinal properties of BEAF were scientifically validated using in vitro and in vivo assays. In vitro antidiabetic effect of the BEAF was conducted using α-Glucosidase and α-Amylase assays. While the antihyperglycemic activity was assessed using two rat models: Alloxan-induced diabetic rats and oral glucose challenged rats. Experimental diabetes was induced by a single intraperitoneal injection of alloxan at a dose of 150 mg/kg and animals with fasting blood glucose levels (BGL) > 200 mg/dL were considered diabetic. Glibenclamide (5 mg/kg) was used as a typical drug.

Results

The BEAF at all tested dose levels (100, 250, and 500 mg/kg) showed a significant decrease in blood glucose level in all the two animal models. Besides, the plant extract exhibited a potent inhibitory effect on α-Amylase and α-Glucosidase activity at a concentration of 1000 µg/mL with 76.17% and 89.37%, respectively.

Conclusion

BEAF exerts in vitro and in vivo antidiabetic effects, these results suggest that the plant extract can be a therapeutic resource in the treatment of diabetes and hyperlipidemia.

Background

Diabetes mellitus is a serious complex multifactorial disorder that imposes huge health and economic burden on societies. Because the currently available medications have many drawbacks, it's important to look for alternative therapies. Medicinal plants utilized in folk medicine are ideal candidates. Therefore, this work assessed the antidiabetic action of n-butanol extract from the whole plant Atractylis flava Desf (BEAF). These ethnomedicinal properties of BEAF were scientifically validated using in vitro and in vivo assays. In vitro antidiabetic effect of the BEAF was conducted using α-Glucosidase and α-Amylase assays. While the antihyperglycemic activity was assessed using two rat models: Alloxan-induced diabetic rats and oral glucose challenged rats. Experimental diabetes was induced by a single intraperitoneal injection of alloxan at a dose of 150 mg/kg and animals with fasting blood glucose levels (BGL) > 200 mg/dL were considered diabetic. Glibenclamide (5 mg/kg) was used as a typical drug.

Results

The BEAF at all tested dose levels (100, 250, and 500 mg/kg) showed a significant decrease in blood glucose level in all the two animal models. Besides, the plant extract exhibited a potent inhibitory effect on α-Amylase and α-Glucosidase activity at a concentration of 1000 µg/mL with 76.17% and 89.37%, respectively.

Conclusion

BEAF exerts in vitro and in vivo antidiabetic effects, these results suggest that the plant extract can be a therapeutic resource in the treatment of diabetes and hyperlipidemia.

Background

Diabetes mellitus is a serious complex multifactorial disorder that imposes huge health and economic burden on societies. Because the currently available medications have many drawbacks, it's important to look for alternative therapies. Medicinal plants utilized in folk medicine are ideal candidates. Therefore, this work assessed the antidiabetic action of n-butanol extract from the whole plant Atractylis flava Desf (BEAF). These ethnomedicinal properties of BEAF were scientifically validated using in vitro and in vivo assays. In vitro antidiabetic effect of the BEAF was conducted using α-Glucosidase and α-Amylase assays. While the antihyperglycemic activity was assessed using two rat models: Alloxan-induced diabetic rats and oral glucose challenged rats. Experimental diabetes was induced by a single intraperitoneal injection of alloxan at a dose of 150 mg/kg and animals with fasting blood glucose levels (BGL) > 200 mg/dL were considered diabetic. Glibenclamide (5 mg/kg) was used as a typical drug.

Results

The BEAF at all tested dose levels (100, 250, and 500 mg/kg) showed a significant decrease in blood glucose level in all the two animal models. Besides, the plant extract exhibited a potent inhibitory effect on α-Amylase and α-Glucosidase activity at a concentration of 1000 µg/mL with 76.17% and 89.37%, respectively.

Conclusion

BEAF exerts in vitro and in vivo antidiabetic effects, these results suggest that the plant extract can be a therapeutic resource in the treatment of diabetes and hyperlipidemia.

Background

Diabetes mellitus is a serious complex multifactorial disorder that imposes huge health and economic burden on societies. Because the currently available medications have many drawbacks, it's important to look for alternative therapies. Medicinal plants utilized in folk medicine are ideal candidates. Therefore, this work assessed the antidiabetic action of n-butanol extract from the whole plant Atractylis flava Desf (BEAF). These ethnomedicinal properties of BEAF were scientifically validated using in vitro and in vivo assays. In vitro antidiabetic effect of the BEAF was conducted using α-Glucosidase and α-Amylase assays. While the antihyperglycemic activity was assessed using two rat models: Alloxan-induced diabetic rats and oral glucose challenged rats. Experimental diabetes was induced by a single intraperitoneal injection of alloxan at a dose of 150 mg/kg and animals with fasting blood glucose levels (BGL) > 200 mg/dL were considered diabetic. Glibenclamide (5 mg/kg) was used as a typical drug.

Results

The BEAF at all tested dose levels (100, 250, and 500 mg/kg) showed a significant decrease in blood glucose level in all the two animal models. Besides, the plant extract exhibited a potent inhibitory effect on α-Amylase and α-Glucosidase activity at a concentration of 1000 µg/mL with 76.17% and 89.37%, respectively.

Conclusion

BEAF exerts in vitro and in vivo antidiabetic effects, these results suggest that the plant extract can be a therapeutic resource in the treatment of diabetes and hyperlipidemia.

Background

Diabetes mellitus is a serious complex multifactorial disorder that imposes huge health and economic burden on societies. Because the currently available medications have many drawbacks, it's important to look for alternative therapies. Medicinal plants utilized in folk medicine are ideal candidates. Therefore, this work assessed the antidiabetic action of n-butanol extract from the whole plant Atractylis flava Desf (BEAF). These ethnomedicinal properties of BEAF were scientifically validated using in vitro and in vivo assays. In vitro antidiabetic effect of the BEAF was conducted using α-Glucosidase and α-Amylase assays. While the antihyperglycemic activity was assessed using two rat models: Alloxan-induced diabetic rats and oral glucose challenged rats. Experimental diabetes was induced by a single intraperitoneal injection of alloxan at a dose of 150 mg/kg and animals with fasting blood glucose levels (BGL) > 200 mg/dL were considered diabetic. Glibenclamide (5 mg/kg) was used as a typical drug.

Results

The BEAF at all tested dose levels (100, 250, and 500 mg/kg) showed a significant decrease in blood glucose level in all the two animal models. Besides, the plant extract exhibited a potent inhibitory effect on α-Amylase and α-Glucosidase activity at a concentration of 1000 µg/mL with 76.17% and 89.37%, respectively.

Conclusion

BEAF exerts in vitro and in vivo antidiabetic effects, these results suggest that the plant extract can be a therapeutic resource in the treatment of diabetes and hyperlipidemia.

Background

Diabetes mellitus is a serious complex multifactorial disorder that imposes huge health and economic burden on societies. Because the currently available medications have many drawbacks, it's important to look for alternative therapies. Medicinal plants utilized in folk medicine are ideal candidates. Therefore, this work assessed the antidiabetic action of n-butanol extract from the whole plant Atractylis flava Desf (BEAF). These ethnomedicinal properties of BEAF were scientifically validated using in vitro and in vivo assays. In vitro antidiabetic effect of the BEAF was conducted using α-Glucosidase and α-Amylase assays. While the antihyperglycemic activity was assessed using two rat models: Alloxan-induced diabetic rats and oral glucose challenged rats. Experimental diabetes was induced by a single intraperitoneal injection of alloxan at a dose of 150 mg/kg and animals with fasting blood glucose levels (BGL) > 200 mg/dL were considered diabetic. Glibenclamide (5 mg/kg) was used as a typical drug.

Results

The BEAF at all tested dose levels (100, 250, and 500 mg/kg) showed a significant decrease in blood glucose level in all the two animal models. Besides, the plant extract exhibited a potent inhibitory effect on α-Amylase and α-Glucosidase activity at a concentration of 1000 µg/mL with 76.17% and 89.37%, respectively.

Conclusion

BEAF exerts in vitro and in vivo antidiabetic effects, these results suggest that the plant extract can be a therapeutic resource in the treatment of diabetes and hyperlipidemia.

Context: More than 500 Centaurea species compose the Asteraceae family, and most of the recent studies made on the species of this genus proved their pharmacological potential, especially to treat chronic illnesses. Aims: To evaluate for the first time the antioxidant, anti-inflammatory, neuroprotective and anti-microbial properties of the n-butanol (nBuOH) and ethyl acetate (EA) extracts of the aerial part of Centaurea tougourensis. Methods: The antioxidant activity was determined by ABTS, galvinoxyl radical, phenanthroline, and reducing power assays, while the antiinflammatory effects were assessed by heat-induced hemolysis and egg albumin denaturation assays. The neuroprotective activity was assessed against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) and the anti-microbial activity by the agar disk diffusion method. Results: Both extracts possess a great antioxidant capacity, but it was considered higher in the n-BuOH extract with respective IC50 values of 8.04 ± 0.21 μg/mL in ABTS assay and 4.25 ± 0.6 μg/mL in GOR assay, while the A0.50 values were 4.46 ± 0.55 μg/mL in phenanthroline assay and 11.16 ± 0.64 μg/mL in reducing power assay. The n-BuOH extract also showed a remarkable anti-inflammatory activity with an EC50 of 120.81 ± 0.2 μg/mL in egg albumin denaturation assay and 154.15 ± 0.14 μg/mL in heat-induced hemolysis assay. The neuroprotective activity of the n-BuOH extract was very strong in both AChE and BChE inhibitory assays with respective IC50 values of 9.8 ± 0.62 μg/mL and 173.53 ± 0.04 μg/mL. EA extract was more active on microbial strains. Conclusions: These encouraging results showed once again the pharmacological potential of Centaurea species

Context: More than 500 Centaurea species compose the Asteraceae family, and most of the recent studies made on the species of this genus proved their pharmacological potential, especially to treat chronic illnesses. Aims: To evaluate for the first time the antioxidant, anti-inflammatory, neuroprotective and anti-microbial properties of the n-butanol (nBuOH) and ethyl acetate (EA) extracts of the aerial part of Centaurea tougourensis. Methods: The antioxidant activity was determined by ABTS, galvinoxyl radical, phenanthroline, and reducing power assays, while the antiinflammatory effects were assessed by heat-induced hemolysis and egg albumin denaturation assays. The neuroprotective activity was assessed against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) and the anti-microbial activity by the agar disk diffusion method. Results: Both extracts possess a great antioxidant capacity, but it was considered higher in the n-BuOH extract with respective IC50 values of 8.04 ± 0.21 μg/mL in ABTS assay and 4.25 ± 0.6 μg/mL in GOR assay, while the A0.50 values were 4.46 ± 0.55 μg/mL in phenanthroline assay and 11.16 ± 0.64 μg/mL in reducing power assay. The n-BuOH extract also showed a remarkable anti-inflammatory activity with an EC50 of 120.81 ± 0.2 μg/mL in egg albumin denaturation assay and 154.15 ± 0.14 μg/mL in heat-induced hemolysis assay. The neuroprotective activity of the n-BuOH extract was very strong in both AChE and BChE inhibitory assays with respective IC50 values of 9.8 ± 0.62 μg/mL and 173.53 ± 0.04 μg/mL. EA extract was more active on microbial strains. Conclusions: These encouraging results showed once again the pharmacological potential of Centaurea species

Context: More than 500 Centaurea species compose the Asteraceae family, and most of the recent studies made on the species of this genus proved their pharmacological potential, especially to treat chronic illnesses. Aims: To evaluate for the first time the antioxidant, anti-inflammatory, neuroprotective and anti-microbial properties of the n-butanol (nBuOH) and ethyl acetate (EA) extracts of the aerial part of Centaurea tougourensis. Methods: The antioxidant activity was determined by ABTS, galvinoxyl radical, phenanthroline, and reducing power assays, while the antiinflammatory effects were assessed by heat-induced hemolysis and egg albumin denaturation assays. The neuroprotective activity was assessed against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) and the anti-microbial activity by the agar disk diffusion method. Results: Both extracts possess a great antioxidant capacity, but it was considered higher in the n-BuOH extract with respective IC50 values of 8.04 ± 0.21 μg/mL in ABTS assay and 4.25 ± 0.6 μg/mL in GOR assay, while the A0.50 values were 4.46 ± 0.55 μg/mL in phenanthroline assay and 11.16 ± 0.64 μg/mL in reducing power assay. The n-BuOH extract also showed a remarkable anti-inflammatory activity with an EC50 of 120.81 ± 0.2 μg/mL in egg albumin denaturation assay and 154.15 ± 0.14 μg/mL in heat-induced hemolysis assay. The neuroprotective activity of the n-BuOH extract was very strong in both AChE and BChE inhibitory assays with respective IC50 values of 9.8 ± 0.62 μg/mL and 173.53 ± 0.04 μg/mL. EA extract was more active on microbial strains. Conclusions: These encouraging results showed once again the pharmacological potential of Centaurea species